Healthcare Industry News: Transdermal
News Release - May 16, 2013
Echo Therapeutics to Unveil Symphony(R) CGM System in WebcastDemonstration coincides with Symphony's upcoming CE Mark pivotal trial
PHILADELPHIA, May 16, 2013 -- (Healthcare Sales & Marketing Network) -- Echo Therapeutics, Inc. (ECTE), a company developing its needle-free Symphony® CGM System as a non-invasive, wireless, Transdermal continuous glucose monitoring system, today announced the unveiling and demonstration of its Symphony CGM System to be used in its regulatory trials. The demonstration will take place during a live webcast following the annual stockholders meeting on Wednesday, May 22 at 10:30am EDT.
A demonstration of the features and functionality of the Symphony CGM System in the critical care setting will follow a corporate presentation from Patrick T. Mooney, M.D., Echo's Chairman and CEO. The demonstration coincides with the final steps in the preparation for the upcoming multi-center CE Mark pivotal trial.
"We are very excited to illustrate the ease of using Symphony. We believe that Symphony will be an important and differentiated candidate for hospital-based glucose monitoring that has the potential to change the paradigm of invasive, episodic glucose monitoring. We also believe that the needle-free, wireless and continuous features and benefits will lead to better long-term patient outcomes," commented Dr. Mooney. "More than ever, we are enthusiastic about the potential of Symphony and we look forward to the commencement of the upcoming pivotal trial."
The webcast will start at approximately 10:30am EDT on Wednesday, May 22. The link to the webcast will be available on the Echo Therapeutics, Inc. website at www.echotx.com under Events in the Investors section, and will be archived for future reference.
About Echo Therapeutics
Echo Therapeutics is developing the Symphony CGM System as a non-invasive, wireless, Transdermal continuous glucose monitoring system. Our target is patients who could benefit from glucose monitoring in the hospital setting, including critical care. Significant opportunity also exists for patients with diabetes to use Symphony in the outpatient setting. Echo is also developing its needle-free skin preparation component of Symphony, the Prelude® SkinPrep System, as a platform technology to enhance drug delivery of topical pharmaceuticals.
Cautionary Statement Regarding Forward Looking Statements
The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo's ongoing studies, including the safety and efficacy of Echo's Symphony CGM System, the failure of future development and preliminary marketing efforts related to Echo's Symphony CGM System, Echo's ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo's and its partners' ability to develop, market and sell the Symphony CGM System, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its Symphony CGM System. These and other risks and uncertainties are identified and described in more detail in Echo's filings with the Securities and Exchange Commission, including, without limitation, its Annual Report on Form 10-K for the year ended December 31, 2012, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. Echo undertakes no obligation to publicly update or revise any forward-looking statements.
Source: Echo Therapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.